These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16806589)

  • 1. Exploring QSAR on 3-aminopyrazoles as antitumor agents for their inhibitory activity of CDK2/cyclin A.
    Samanta S; Debnath B; Basu A; Gayen S; Srikanth K; Jha T
    Eur J Med Chem; 2006 Oct; 41(10):1190-5. PubMed ID: 16806589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
    Singh SK; Dessalew N; Bharatam PV
    Eur J Med Chem; 2006 Nov; 41(11):1310-9. PubMed ID: 16890327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An efficient tool for identifying inhibitors based on 3D-QSAR and docking using feature-shape pharmacophore of biologically active conformation--a case study with CDK2/cyclinA.
    Mascarenhas NM; Ghoshal N
    Eur J Med Chem; 2008 Dec; 43(12):2807-18. PubMed ID: 18037537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors.
    Pevarello P; Fancelli D; Vulpetti A; Amici R; Villa M; Pittalà V; Vianello P; Cameron A; Ciomei M; Mercurio C; Bischoff JR; Roletto F; Varasi M; Brasca MG
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1084-90. PubMed ID: 16290148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling.
    Yuan H; Liu H; Tai W; Wang F; Zhang Y; Yao S; Ran T; Lu S; Ke Z; Xiong X; Xu J; Chen Y; Lu T
    SAR QSAR Environ Res; 2013 Oct; 24(10):795-817. PubMed ID: 23941641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization.
    Pevarello P; Brasca MG; Orsini P; Traquandi G; Longo A; Nesi M; Orzi F; Piutti C; Sansonna P; Varasi M; Cameron A; Vulpetti A; Roletto F; Alzani R; Ciomei M; Albanese C; Pastori W; Marsiglio A; Pesenti E; Fiorentini F; Bischoff JR; Mercurio C
    J Med Chem; 2005 Apr; 48(8):2944-56. PubMed ID: 15828833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
    Ibrahim DA; Ismail NS
    Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, pharmacological activity and comparative QSAR modeling of 1,5-N,N'-substituted-2-(substituted naphthalenesulphonyl) glutamamides as possible anticancer agents.
    Halder AK; Adhikary N; Maity MK; Jha T
    Eur J Med Chem; 2010 May; 45(5):1760-71. PubMed ID: 20133022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.
    Dessalew N; Bharatam PV
    Eur J Med Chem; 2007 Jul; 42(7):1014-27. PubMed ID: 17335939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible anticancer agents: QSAR analogs of glutamamide: synthesis and pharmacological activity of 1,5-N,N'-disubstituted-2-(substituted benzenesulphonyl) glutamamides.
    Samanta S; Alam SM; Panda P; Jha T
    Eur J Med Chem; 2009 Jan; 44(1):70-82. PubMed ID: 18456372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.
    Pevarello P; Brasca MG; Amici R; Orsini P; Traquandi G; Corti L; Piutti C; Sansonna P; Villa M; Pierce BS; Pulici M; Giordano P; Martina K; Fritzen EL; Nugent RA; Casale E; Cameron A; Ciomei M; Roletto F; Isacchi A; Fogliatto G; Pesenti E; Pastori W; Marsiglio A; Leach KL; Clare PM; Fiorentini F; Varasi M; Vulpetti A; Warpehoski MA
    J Med Chem; 2004 Jun; 47(13):3367-80. PubMed ID: 15189033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virtual screening studies to design potent CDK2-cyclin A inhibitors.
    Vadivelan S; Sinha BN; Irudayam SJ; Jagarlapudi SA
    J Chem Inf Model; 2007; 47(4):1526-35. PubMed ID: 17523616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A practical synthesis of the major 3-hydroxy-2-pyrrolidinone metabolite of a potent CDK2/cyclin A inhibitor.
    Nesi M; Borghi D; Brasca MG; Fiorentini F; Pevarello P
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3205-8. PubMed ID: 16616492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity.
    Choi SJ; Lee JE; Jeong SY; Im I; Lee SD; Lee EJ; Lee SK; Kwon SM; Ahn SG; Yoon JH; Han SY; Kim JI; Kim YC
    J Med Chem; 2010 May; 53(9):3696-706. PubMed ID: 20361800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D-QSAR CoMFA studies on bis-coumarine analogues as urease inhibitors: a strategic design in anti-urease agents.
    Zaheer-ul-Haq ; Lodhi MA; Ahmad Nawaz S; Iqbal S; Mohammed Khan K; Rode BM; Atta-ur-Rahman ; Choudhary MI
    Bioorg Med Chem; 2008 Mar; 16(6):3456-61. PubMed ID: 18280742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational evaluation of some indenopyrazole derivatives as anticancer compounds; application of QSAR and docking methodologies.
    Shahlaei M; Fassihi A; Saghaie L; Arkan E; Madadkar-Sobhani A; Pourhossein A
    J Enzyme Inhib Med Chem; 2013 Feb; 28(1):16-32. PubMed ID: 21999517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring structural requirements of 1-N-substituted thiocarbamoyl-3-phenyl-2-pyrazolines as antiamoebic agents using comparative QSAR modelling.
    Adhikari N; Maiti MK; Jha T
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4021-6. PubMed ID: 20561784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.
    Finlay MR; Acton DG; Andrews DM; Barker AJ; Dennis M; Fisher E; Graham MA; Green CP; Heaton DW; Karoutchi G; Loddick SA; Morgentin R; Roberts A; Tucker JA; Weir HM
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4442-6. PubMed ID: 18617397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.